

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

COALITION FOR AFFORDABLE DRUGS X LLC,  
Petitioner,

v.

ANACOR PHARMACEUTICALS, INC.,  
Patent Owner.

Case No. IPR2015-01776  
Patent No. 7,582,621

---

**PATENT OWNER PRELIMINARY RESPONSE  
PURSUANT TO 37 C.F.R. § 42.107**

DC: 5863873-19

## LIST OF EXHIBITS

EXHIBIT	DESCRIPTION
Ex. 2001	FDA Approved Label for KERYDIN <sup>®</sup> (Rev. 3/2015)
Ex. 2002	Fairchild <i>et al.</i> , <i>In Vitro Determination of Uptake, Retention, Distribution, Biological Efficacy, and Toxicity of Boronated Compounds for Neutron Capture Therapy: A Comparison of Porphyrins with Sulfhydryl Boron Hydrides</i> , <i>Cancer Res.</i> , vol. 50, pp. 4860-65 (1990)
Ex. 2003	Charif <i>et al.</i> , <i>A Historical Perspective on Onychomycosis</i> , <i>Dermatol. Ther.</i> vol. 3, pp. 43-45 (1997)
Ex. 2004	Heath <i>et al.</i> , <i>Fatty Acid Biosynthesis as a Target for Novel Antibacterials</i> , <i>Curr. Opin. Invest. Drugs</i> , vol. 5, pp. 146-53 (2004)
Ex. 2005	Baldock <i>et al.</i> , <i>A Mechanism of Drug Action Revealed by Structural Studies of Enoyl Reductase</i> , <i>Science</i> , vol. 274, pp. 2107-10 (1996)
Ex. 2006	Biobor, R.E.D. Facts, EPA-738-R-93-004 (June 1993), <a href="http://nepis.epa.gov/Exe/ZyPDF.cgi?Dockey=200009P5.PDF">http://nepis.epa.gov/Exe/ZyPDF.cgi?Dockey=200009P5.PDF</a>
Ex. 2007	Lefkovits <i>et al.</i> , <i>Direct Thrombin Inhibitors in Cardiovascular Medicine</i> , <i>Circulation</i> , vol. 90, pp. 1522-36 (1994)
Ex. 2008	Grassberger <i>et al.</i> , <i>Preparation and Antibacterial Activities of New 1,2,3-Diazaborine Derivatives and Analogs</i> , <i>J. Med. Chem.</i> , vol. 27, no. 8, pp. 947-53 (1984)
Ex. 2009	Baldock <i>et al.</i> , <i>Mechanism of Action of Diazaborines</i> , <i>Biochem. Pharm.</i> , vol. 55, pp. 1541-49 (1998)
Ex. 2010	Heindel <i>et al.</i> , <i>The Developmental Toxicity of Boric Acid in Mice, Rats, and Rabbits</i> , <i>Environ. Health Perspect.</i> , vol. 102, suppl. 7, pp. 107-12 (1994)
Ex. 2011	Richardson, <i>Clinical Update: Proteasome Inhibitors in Hematologic Malignancies</i> , <i>Cancer Treatment Rev.</i> , vol. 29, suppl. 1, pp. 33-39 (2003)
Ex. 2012	Bross <i>et al.</i> , <i>Approval Summary for Bortezomib for injection in the Treatment of Multiple Myeloma</i> , <i>Clin. Cancer Res.</i> , vol. 10, pp. 3954-64 (2004)
Ex. 2013	Adams, <i>Proteasome Inhibitors as Therapeutic Agents</i> , <i>Expert Opin. Ther. Patents</i> , vol. 13, no. 1, pp. 45-57 (2003)
Ex. 2014	Dorland's Illustrated Medical Dictionary, p. 211 (29th ed. 2000)

EXHIBIT	DESCRIPTION
Ex. 2015	Stedman's Medical Dictionary, p. 204 (27th ed. 2000)
Ex. 2016	Random House Webster's Unabridged Dictionary, p. 209 (2nd ed. 2001)
Ex. 2017	Jordon <i>et al.</i> , <i>Boric Acid Poisoning: A Report of a Fatal Adult Case from Cutaneous Use. A Critical Evaluation of the Use of This Drug in Dermatologic Practice</i> , JAMA Derm, vol. 75, pp. 720-28 (1957).
Ex. 2018	Zhdankin <i>et al.</i> , <i>Synthesis and Structure of Benzoxaboroles: Novel Organoboron Heterocycles</i> , Tetrahedron Lett., vol. 40, pp. 6705-08 (1999)
Ex. 2019	Triggle, <i>Pharmacological Receptors: A Century of Discovery—and More</i> , Pharm. Acta Helvetiae, vol. 74, pp. 79-84 (2000)
Ex. 2020	Larsen <i>et al.</i> , <i>The Prevalence of Onychomycosis in Patients with Psoriasis and Other Skin Diseases</i> , Acta Derm. Venereol., vol 83, pp. 206-09 (2003)
Ex. 2021	Tatsumi <i>et al.</i> , <i>Therapeutic Efficacy of Topically Applied KP-103 Against Experimental Tinea Unguium in Guinea Pigs in Comparison with Amorolfine and Terbinafine</i> , Antimicrobial Agents and Chemotherapy, vol. 46, no. 12, pp. 3797-3801 (2002)
Ex. 2022	Osborne <i>et al.</i> , <i>Antifungal Drug Response in an In Vitro Model of Dermatophyte Nail Infection</i> , Med. Mycol., vol. 42, pp. 159-63 (2004)
Ex. 2023	Favre <i>et al.</i> , <i>Comparison of In Vitro Activities of 17 Antifungal Drugs Against a Panel of 20 Dermatophytes by Using a Microdilution Assay</i> , J. Clin. Microbiol., vol. 41, no. 10, pp. 4817-19 (2003)
Ex. 2024	Sangster, <i>Octanol-Water Partition Coefficients of Simple Organic Compounds</i> , J. Phys. Chem. Ref. Data, vol. 18, pp. 1111-1227 (1989)
Ex. 2025	Powers <i>et al.</i> , <i>Structure-Based Approach for Binding Site Identification on AmpC <math>\beta</math>-Lactamase</i> , J. Med. Chem., vol. 45, pp. 3222-34 (2002)
Ex. 2026	Boric Acid, R.E.D. Facts, EPA-738-F-93-006 (Sept. 1993), <a href="http://archive.epa.gov/pesticides/reregistration/web/pdf/0024fact.pdf">http://archive.epa.gov/pesticides/reregistration/web/pdf/0024fact.pdf</a>
Ex. 2027	Vander Straten <i>et al.</i> , <i>Cutaneous Infections: Dermatophytosis, Onychomycosis, and Tinea Versicolor</i> , Infect. Dis. Clinics N. Am., vol. 17, pp. 87-112 (2003)

## TABLE OF CONTENTS

I.	INTRODUCTION .....	1
II.	BACKGROUND .....	6
	A. Anacor’s Surprising Discovery That Tavaborole Treats Onychomycosis .....	6
	B. 2005 State of the Art: Boron-containing Compounds Are Toxic .....	7
III.	LEVEL OF ORDINARY SKILL IN THE ART .....	15
IV.	CLAIM CONSTRUCTION .....	16
	A. 1,3-dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole .....	17
	B. Therapeutically Effective Amount .....	18
	C. Tinea Unguium .....	18
	D. Dermatological Diseases and Tinea Pedis .....	18
V.	THE PETITION FAILS TO DEMONSTRATE A REASONABLE LIKELIHOOD THAT ANY CLAIM OF THE ’621 PATENT IS UNPATENTABLE .....	19
	A. Ground 1: The Petition Fails to Demonstrate That Claims 1-12 Are Unpatentable Over Austin in View of Brehove .....	19
	1. A POSA would not have started with a compound selected from Austin .....	20
	2. A POSA would not have selected tavaborole from among Austin’s millions of compounds .....	23
	a) Austin’s preferred boron-containing industrial biocides include millions of compounds .....	24
	b) Austin prefers other benzoxaboroles over tavaborole .....	26
	c) Tavaborole’s molecular weight does not support its preference over other compounds .....	27

3.	The Petition provides no credible reason to combine Austin and Brehove.....	29
a)	Brehove does not demonstrate that its dioxaborinanes, or the oxaboroles of Austin, are not toxic .....	30
b)	Brehove’s dioxaborinanes are structurally different from Austin’s oxaboroles, including tavaborole .....	32
c)	Brehove does not make tavaborole, one of Austin’s millions of compounds, obvious to try .....	35
d)	Brehove does not supply a reasonable expectation of success .....	37
4.	The Petition fails to provide articulated reasoning supported by evidence for treating onychomycosis and other infections requiring nail penetration (claims 4, 6, 8, 9, and 11).....	38
B.	Ground 2: The Petition Fails to Demonstrate That Claims 1-12 Are Unpatentable Over Austin in View of Freeman.....	45
1.	A POSA would not have selected any compound from Austin, and certainly not tavaborole .....	46
2.	The petition provides no credible reason to combine Austin and Freeman .....	47
a)	Freeman does not remedy the expectation that Austin’s benzoxaboroles would be toxic.....	47
b)	Freeman’s phenyl boronic acids are structurally different from Austin’s benzoxaboroles, including tavaborole .....	48
c)	Freeman does not supply a reasonable expectation that any of Austin’s compounds would succeed .....	51
d)	Freeman does not make tavaborole, one of Austin’s millions of compounds, obvious to try .....	54

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.